SB 646 requires manufacturers and brand owners of prenatal multivitamins sold or offered in California to test a representative sample of each lot for arsenic, cadmium, lead, and mercury beginning January 1, 2027. Labs that run the analyses must meet ISO/IEC 17025 accreditation, use analytical methods at least as sensitive as the FDA’s referenced ICP‑MS procedure, and demonstrate proficiency at quantifying metals down to very low levels.
The bill also forces brand owners to post lot‑level test results and supplement facts on a single webpage for the duration of the product’s shelf life plus one month, make that information publicly accessible without requiring proof of purchase, and place package and online product‑page notices linking to the test results for items shipped on or after January 1, 2027 (with a sale prohibition for products lacking those statements effective January 1, 2030). Both manufacturers and brand owners must provide test results to an authorized agent of the California Department of Public Health on request; noncompliance is barred from sale in California.
At a Glance
What It Does
The bill requires per‑lot heavy‑metal testing of bulk and packaged prenatal multivitamins at accredited, proficient laboratories using methods at least as sensitive as the FDA’s ICP‑MS protocol. Brand owners must publicly post lot‑level heavy‑metal names and levels alongside the supplement facts on a single webpage and include package and online notices linking to those results.
Who It Affects
This regime applies to anyone who manufactures or places a prenatal multivitamin in the California market: brand owners (the owner or licensee of the most prominent trademark), contract manufacturers, and the labs that test these products. Retailers and online marketplaces must carry products with the mandated package or online notices once the phase‑in dates apply.
Why It Matters
The measure creates a standardized testing and transparency regime for prenatal supplements — a product category aimed at a high‑sensitivity population — which will change compliance, procurement, and labeling workflows across the supply chain and may influence sourcing or formulation decisions by manufacturers and buying behavior by health‑care providers and consumers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB 646 creates a state‑level testing and disclosure framework focused on prenatal multivitamins — dietary supplements marketed for people who are pregnant, planning pregnancy, or lactating. The law covers both bulk finished product (the lot before packaging) and the packaged product sold to consumers or health‑care professionals; it defines who counts as the ‘‘brand owner’’ versus the manufacturer so responsibilities are allocated to the company whose trademark is most prominent and to the entity that actually manufactures the lot.
For each lot that will be sold or offered in California, the manufacturer must test a representative sample for four named heavy metals: arsenic, cadmium, lead, and mercury. The tests must be performed at a ‘‘proficient’’ laboratory: one accredited to ISO/IEC 17025 for the relevant heavy‑metal testing, using an analytical method at least as sensitive as the FDA’s Elemental Analysis Manual (the ICP‑MS microwave‑digestion approach cited in the bill), and demonstrating proficiency by achieving a z‑score within ±2 on independent proficiency tests at or below the stated quantitation level.Brand owners must publish on their websites, for the product’s shelf life plus one month, the name and measured level of each heavy metal in each lot along with the supplement facts panel — all on a single web page and accessible without requiring a UPC, lot number, or purchase proof.
The bill also requires a clear package notice on the outermost shipping package for retail shipments and a statement with a hyperlink on online product pages for consumer shipments, effective for shipments on or after January 1, 2027; by January 1, 2030, the statute bars sale in California of any prenatal multivitamin that lacks the specified packaging or online statements. Both manufacturers and brand owners must provide test results to an authorized agent of the Department of Public Health on request; if the brand owner does not perform the testing, they may meet the obligation by supplying the manufacturer’s results.
The Five Things You Need to Know
The bill defines “heavy metals” narrowly as arsenic, cadmium, lead, and mercury.
Laboratories must demonstrate proficiency in quantifying each heavy metal to 10 micrograms per kilogram (10 μg/kg) or less and achieve a z‑score ≤ ±2 in an independent proficiency test.
The required analytical approach must be at least as sensitive and specific as Section 4.7 of FDA’s Elemental Analysis Manual (the ICP‑MS method using microwave‑assisted digestion).
Brand owners must post lot‑level heavy‑metal names and levels plus the supplement facts on a single webpage for the product’s shelf life plus one month, and that information must be publicly available without requiring UPC, lot number, or proof of purchase.
Products shipped to retailers or consumers on or after January 1, 2027 must include a package or online product‑page statement linking to test results; starting January 1, 2030, selling a prenatal multivitamin in California without those statements is prohibited.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Who is a brand owner, what counts as a prenatal multivitamin, and scope
This section draws the boundary lines for obligations. ‘‘Brand owner’’ is the trademark owner most prominently shown on the principal display panel; contract manufacturers are separate and may carry testing duties if they perform manufacturing. ‘‘Prenatal multivitamin’’ is defined by intended use (pregnant, planning pregnancy, lactating) and covers multiple dosage forms (capsules, gummies, powders, liquids). The statute distinguishes bulk finished product (pre‑packaging) from packaged product, which matters because testing and sampling apply to each lot of finished product whether packaged or not.
Per‑lot testing at a proficient laboratory
The manufacturer must test a representative sample from each lot of bulk or packaged prenatal multivitamin for the four named heavy metals. The ‘‘representative sample’’ obligation imports industry sampling logic — random or otherwise rational sampling — but leaves specific sampling plans to the operator’s quality system. Practically, manufacturers must set sampling protocols that yield defensible, lot‑level results and retain supporting documentation for inspection.
Accreditation, analytical method, and proficiency thresholds
Laboratories (including an in‑house lab) must be accredited to ISO/IEC 17025:2017 for the relevant analyses, use an analytical method at least as sensitive as the FDA’s cited ICP‑MS microwave digestion procedure, and prove proficiency by quantifying metals to ≤10 μg/kg with a z‑score ≤ ±2 on independent proficiency tests. Where federal regulations conflict, the federal rule controls — the bill explicitly preserves that interplay — but otherwise California sets a high bar for lab competence and sensitivity.
Department access to results and public web disclosure requirements
Both manufacturers and brand owners must provide test results to an authorized department agent on request; a non‑manufacturing brand owner can supply the manufacturer’s results to comply. Separately, brand owners must post, on a single web page, the name and measured level of each heavy metal for each lot together with the supplement facts panel. The information must remain posted for shelf life plus one month, be reachable without asking consumers for proof of purchase or lot identifiers, and include a prominent statement and a link to FDA resources on heavy metals in food.
Package/online notice timing and sale ban for noncompliant products
For products shipped to retailers or consumers on or after January 1, 2027, the outermost package for retail shipments must name the web address with the test results, and online product‑detail pages for consumer shipments must include a hyperlink to the results. The bill phases in a strict prohibition: beginning January 1, 2030, a prenatal multivitamin lacking the specified packaging or online statements may not be sold or offered in California. That gives supply chains a multi‑year window to comply with labeling and web‑posting duties.
Penalties, local mandate, and reimbursement carve‑out
The bill makes noncompliance with the chapter a bar to sale in California and creates a new crime or infraction for violation, which is the basis for the legislative finding that no state reimbursement is required under the California Constitution. That means local entities could face enforcement or prosecutorial involvement without the state funding additional compliance capacity.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Expectant and lactating people and those planning pregnancy — get lot‑level heavy‑metal data and supplement facts in one place without needing purchase proof, improving informed choice at a vulnerable life stage.
- Health‑care providers and pharmacists — can access lot‑level contamination data to better advise patients about product selection or switch prescriptions to brands with lower detected levels.
- Public health agencies and researchers — gain a structured, accessible data stream on heavy‑metal levels in prenatal supplements, which supports exposure surveillance and may inform future regulation or guidance.
Who Bears the Cost
- Brand owners and manufacturers — must implement per‑lot sampling, pay for accredited lab analyses, maintain web disclosure infrastructure, and change packaging/online content, with recurring costs tied to lot volume.
- Contract manufacturers and small supplement companies — may face disproportionate compliance burdens, accreditation and proficiency testing costs, and potential loss of retail listings if unable to demonstrate compliant labeling or testing.
- Testing laboratories and in‑house labs — must obtain or expand ISO/IEC 17025 accreditation, run independent proficiency testing, and meet method sensitivity and reporting standards, creating capacity and cost pressures; regulators also bear enforcement and inspection workloads.
Key Issues
The Core Tension
The statute’s central dilemma is balancing transparency for a medically‑sensitive population against the real costs and market consequences of strict testing and disclosure: strong consumer‑facing data can improve choice and public health surveillance, but it also risks imposing heavy compliance costs, reducing product availability, and prompting market responses that may not correlate with actual health risk.
The bill fixes three clear policy goals — per‑lot testing, high lab standards, and public disclosure — but leaves several implementation uncertainties. ‘‘Representative sample’’ is intentionally flexible, which lets manufacturers tailor sampling to their processes but creates a potential enforcement gap where the department and industry may disagree about what constitutes sufficient sampling to represent a lot. The law’s performance hinge is on laboratory capacity: ISO/IEC 17025 accreditation and the proficiency thresholds are technically demanding, and California’s sudden incremental demand for highly proficient ICP‑MS testing could strain third‑party labs or force manufacturers to invest in in‑house capabilities.
Another area of tension is how consumers and clinicians will interpret trace detections. The bill requires publication of numeric results without requiring contextual risk communication beyond a single explanatory statement and a link to FDA resources.
That may produce market effects — reformulation, ingredient‑sourcing shifts, or product withdrawals — driven by caution or misinterpretation of trace environmental background levels rather than demonstrated health risk. Finally, although the statute preserves federal preemption where federal rules conflict, practical disputes can arise over method equivalence, interstate shipments, and whether packaging statements meet federal labeling rules or create trade friction for national and international brands.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.